Antibiotics produced by Streptomyces.

Streptomyces is a genus of Gram-positive bacteria that grows in various environments, and its shape resembles filamentous fungi. The morphological differentiation of Streptomyces involves the formation of a layer of hyphae that can differentiate into a chain of spores. The most interesting property of Streptomyces is the ability to produce bioactive secondary metabolites, such as antifungals, antivirals, antitumorals, anti-hypertensives, immunosuppressants, and especially antibiotics. The production of most antibiotics is species specific, and these secondary metabolites are important for Streptomyces species in order to compete with other microorganisms that come in contact, even within the same genre. Despite the success of the discovery of antibiotics, and advances in the techniques of their production, infectious diseases still remain the second leading cause of death worldwide, and bacterial infections cause approximately 17 million deaths annually, affecting mainly children and the elderly. Self-medication and overuse of antibiotics is another important factor that contributes to resistance, reducing the lifetime of the antibiotic, thus causing the constant need for research and development of new antibiotics.

[1]  D. Pompliano,et al.  Drugs for bad bugs: confronting the challenges of antibacterial discovery , 2007, Nature Reviews Drug Discovery.

[2]  Afreenish Hassan,et al.  Evaluation of different detection methods of biofilm formation in the clinical isolates. , 2011, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

[3]  Jun Ishikawa,et al.  Genome Sequence of the Streptomycin-Producing Microorganism Streptomyces griseus IFO 13350 , 2008, Journal of bacteriology.

[4]  Christoph Freiberg,et al.  Functional genomics in antibacterial drug discovery. , 2005, Drug discovery today.

[5]  Guoping Zhao,et al.  SarA influences the sporulation and secondary metabolism in Streptomyces coelicolor M145. , 2008, Acta biochimica et biophysica Sinica.

[6]  J. Martínez,et al.  A global view of antibiotic resistance. , 2009, FEMS microbiology reviews.

[7]  Mark S Butler,et al.  Natural products--the future scaffolds for novel antibiotics? , 2006, Biochemical pharmacology.

[8]  Z. Daoud,et al.  Antibiotic consumption as a driver for resistance in Staphylococcus aureus and Escherichia coli within a developing region. , 2010, American journal of infection control.

[9]  N. Brunner,et al.  How many modes of action should an antibiotic have? , 2008, Current opinion in pharmacology.

[10]  R. Aminov,et al.  The role of antibiotics and antibiotic resistance in nature. , 2009, Environmental microbiology.

[11]  J. Poulain,et al.  Complete Genome Sequence of Streptomyces cattleya NRRL 8057, a Producer of Antibiotics and Fluorometabolites , 2011, Journal of bacteriology.

[12]  Jesús Silva-Sánchez,et al.  Genética y genómica enfocadas en el estudio de la resistencia bacteriana , 2009 .

[13]  Christopher T. Walsh,et al.  Antibiotics for Emerging Pathogens , 2009, Science.

[14]  Wenjun Li,et al.  Isolation, Diversity, and Antimicrobial Activity of Rare Actinobacteria from Medicinal Plants of Tropical Rain Forests in Xishuangbanna, China , 2009, Applied and Environmental Microbiology.

[15]  S. Projan,et al.  Why is big Pharma getting out of antibacterial drug discovery? , 2003, Current opinion in microbiology.

[16]  Diarmaid Hughes,et al.  Antibiotic resistance and its cost: is it possible to reverse resistance? , 2010, Nature Reviews Microbiology.

[17]  E. Brown,et al.  New screens and targets in antibacterial drug discovery. , 2009, Current opinion in microbiology.

[18]  Roy Kishony,et al.  Drug interactions and the evolution of antibiotic resistance , 2009, Nature Reviews Microbiology.

[19]  H. Brötz-Oesterhelt,et al.  Postgenomic strategies in antibacterial drug discovery. , 2010, Future microbiology.

[20]  A. C. O. Silveira,et al.  Prevalence of carbapenem resistant Pseudomonas aeruginosa and Acinetobacter baumannii in high complexity hospital. , 2010, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

[21]  Alastair D Hay,et al.  Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis , 2010, BMJ : British Medical Journal.

[22]  Klas Flärdh,et al.  Streptomyces morphogenetics: dissecting differentiation in a filamentous bacterium , 2009, Nature Reviews Microbiology.

[23]  Simone Ulrich Picoli,et al.  Avaliação fenotípica da enzima Klebsiella pneumoniae carbapenemase (KPC) em Enterobacteriaceae de ambiente hospitalar , 2010 .

[24]  Heather K. Allen,et al.  Call of the wild: antibiotic resistance genes in natural environments , 2010, Nature Reviews Microbiology.

[25]  C. Salgado,et al.  The association between antibiotic use and resistance: the role of secondary antibiotics , 2010, European Journal of Clinical Microbiology & Infectious Diseases.

[26]  M. Watve,et al.  How many antibiotics are produced by the genus Streptomyces? , 2001, Archives of Microbiology.

[27]  R. H. Baltz Renaissance in antibacterial discovery from actinomycetes. , 2008, Current opinion in pharmacology.

[28]  Michelle D. Brazas,et al.  Using microarray gene signatures to elucidate mechanisms of antibiotic action and resistance. , 2005, Drug discovery today.

[29]  K. Bush Antibacterial drug discovery in the 21st century. , 2004, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[30]  Won-Jae Chi,et al.  Functional analysis of SGR4635-induced enhancement of pigmented antibiotic production in Streptomyces lividans , 2011, The Journal of Microbiology.

[31]  V. Braun,et al.  Gene Cluster Involved in the Biosynthesis of Griseobactin, a Catechol-Peptide Siderophore of Streptomyces sp. ATCC 700974 , 2009, Journal of bacteriology.

[32]  Yoshiyuki Sakaki,et al.  Genome sequence of an industrial microorganism Streptomyces avermitilis: Deducing the ability of producing secondary metabolites , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[33]  H. Nikaido Multidrug resistance in bacteria. , 2009, Annual review of biochemistry.

[34]  Hiroki Ikeuchi,et al.  Impact of a hospital-wide programme of heterogeneous antibiotic use on the development of antibiotic-resistant Gram-negative bacteria. , 2010, The Journal of hospital infection.

[35]  I. Kozone,et al.  Streptomyces associated with a marine sponge Haliclona sp.; biosynthetic genes for secondary metabolites and products. , 2011, Environmental microbiology.

[36]  R. Grol,et al.  Antibiotic prescribing in hospitals: a social and behavioural scientific approach. , 2010, The Lancet. Infectious diseases.

[37]  K. Chater,et al.  The evolution of development in Streptomyces analysed by genome comparisons. , 2006, FEMS microbiology reviews.

[38]  Daniel Jones The antibacterial lead discovery challenge: a recent report provides a rare example of a potential new class of antibiotics. Dan Jones investigates the difficulties of finding such drugs , 2010 .

[39]  Z. Deng,et al.  Identification of a Gene Negatively Affecting Antibiotic Production and Morphological Differentiation in Streptomyces coelicolor A3(2) , 2006, Journal of bacteriology.

[40]  Gerard D. Wright,et al.  Antibiotic resistance in the environment: a link to the clinic? , 2010, Current opinion in microbiology.

[41]  A. Boggs,et al.  Antibacterial drug discovery: is small pharma the solution? , 2004, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[42]  Tracy Palmer,et al.  The complex extracellular biology of Streptomyces. , 2010, FEMS microbiology reviews.

[43]  A. Hsiung,et al.  Antimicrobial susceptibility of Gram-negative bacteria in Brazilian hospitals: the MYSTIC Program Brazil 2003. , 2005, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

[44]  B. Eisenstein The antibacterial lead discovery challenge , 2010, Nature Reviews Drug Discovery.

[45]  F. Lerma,et al.  [Antibiotic policy in critical patients]. , 2010, Medicina intensiva.

[46]  F. Tuon,et al.  Klebsiella ESBL bacteremia-mortality and risk factors. , 2011, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

[47]  D. Tomalia,et al.  Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications. , 2001, Drug discovery today.

[48]  Jun Wang,et al.  Platensimycin is a selective FabF inhibitor with potent antibiotic properties , 2006, Nature.

[49]  E. Johansson,et al.  Antibiotic use, resistance development and environmental factors: a qualitative study among healthcare professionals in Orissa, India , 2010, BMC public health.

[50]  I Chopra,et al.  Exploiting current understanding of antibiotic action for discovery of new drugs , 2002, Symposium series.

[51]  R. Loria,et al.  Streptomyces scabies 87-22 contains a coronafacic acid-like biosynthetic cluster that contributes to plant-microbe interactions. , 2010, Molecular plant-microbe interactions : MPMI.

[52]  Prabhavathi Fernandes,et al.  Antibacterial discovery and development—the failure of success? , 2006, Nature Biotechnology.

[53]  B. Barrell,et al.  Complete genome sequence of the model actinomycete Streptomyces coelicolor A3(2) , 2002, Nature.

[54]  J. Collins,et al.  How antibiotics kill bacteria: from targets to networks , 2010, Nature Reviews Microbiology.

[55]  C. Fishwick,et al.  Structure-based discovery of antibacterial drugs , 2010, Nature Reviews Microbiology.